CME
The burden of non-communicable disease in South Africa (SA) is escalating. Undiagnosed and uncontrolled diabetes mellitus (DM) are common in patients requiring surgery. Access to resources and expertise to safely control blood glucose levels in the perioperative period are variable in the SA public healthcare system. The combination of an increasing burden of disease and inadequate perioperative diabetes management is likely to increase surgical complication rates, mortality and cost of care.
This article focuses on perioperative diabetes management of type 1 and type 2 DM patients who are undergoing surgery in a noncritical care setting. Obstetric, paediatric and critical care patients are excluded from this discussion.
Burden of disease
Type 2 DM is the most common type of diabetes, representing >90% of the DM disease burden in SA. The International Diabetes Federation reports that there are currently ~1.8 million adults in SA known to have DM, while a further 1.5 million adults remain undiagnosed. [1] The SA National Health and Nutrition Examination Survey (SANHANES) 2012 showed a national prevalence of abnormal glucose regulation of 18.6%, varying according to ethnicity and degree of urbanisation. According to SANHANES, 45% of people with diabetes were previously undiagnosed. [2] Over the past decade, DM has become one of the major underlying causes of mortality globally; in SA it now ranks second only to tuberculosis. [3] The SA Surgical Outcomes Study (SASOS) reports a 10.2% prevalence of diabetes in our surgical population (5.8% non-insulin dependent, and 4.4% insulin dependent). [4] 
Diabetes mellitus in the perioperative context
The perioperative period is associated with worsening glycaemic control, probably due to the stress response of surgery. [5] Starvation, tissue trauma and pain lead to increased levels of pro-inflammatory mediators and circulating stress hormones. These substances alter insulin secretion and sensitivity, producing a state of relative insulin resistance, protein catabolism and lipolysis with liberation of free fatty acids. This state can extend for multiple days into the postoperative period, driving adverse patient outcomes. [6] These include increased mortality, increased length of hospital stay, as well as increased infective (surgical site infections, urinary tract infections and pneumonia) and non-infective complications (cardiac events, acute kidney injury and stroke). [7] Protocol-driven quality improvement projects result in improved perioperative glycaemic control, but strict control strategies increase hypoglycaemic events. [8, 9] As hypoglycaemia has been linked to mortality, it is essential to avoid the condition by targeting a perioperative blood glucose level in the range of 6.0 -10.0 mmol/L. [10] A capillary blood glucose (CBG) measurement up to 12.0 mmol/L may be tolerated for brief periods if it is regularly monitored and expected to decrease. [11, 12] Hyperglycaemia in the perioperative period may be due to physiological stress and should not be diagnosed as DM without input from the local diabetes healthcare provider. Stress hyperglycaemia without DM is a poorly understood entity, the management of which remains unclear.
control and invasiveness of the planned surgery. Where available, a glycated haemoglobin (HbA1c) should be used to determine adequacy of glycaemic control in those diagnosed with diabetes. An elevated HbA1c correlates with poor patient outcomes after surgery and an HbA1c >8.5% (69 mmol/mol) warrants postponement of elective surgery. [11, 12] More stringent cut-off values are recommended by some, but may currently be unattainable in many parts of SA. [14] The patient's comorbidities and glycaemic control should always be optimised before elective surgery. In an emergency, there is little time for optimisation, as surgery must proceed promptly. Often though, patients present for surgery that is time sensitive. In this 'grey zone' between elective and emergency, the timing of surgery should be determined by a multidisciplinary team with a patientcentred discussion about how best to balance risk and benefit. [15] The decision to proceed with surgery in the face of uncontrolled DM must acknowledge the increased risk to the patient and define ways to manage this risk.
Resources and access to expertise vary among healthcare centres. It is therefore important to choose an appropriate perioperative glycaemic management plan. Although many options are available, four are commonly used and recommended (Table 1 ):
• modification of usual treatment (Tables 2 and 3) • basal-bolus subcutaneous (SC) insulin ( Fig. 1) • Alberti's glucose-insulin-potassium (GIK) intravenous infusion (Box 1) • variable rate intravenous insulin infusion (VRIII) (Fig. 2) .
Monotherapy with SC short-or rapid-acting insulin according to a sliding scale is not recommended for in-hospital management of DM, as it increases the risk of hypoglycaemia and provides inferior glycaemic control. [16, 17] In all cases, limiting of the starvation period has to be planned, as well as where the patient will be managed postoperatively (day case, surgical ward or high-care facility). For short starvation periods (one missed meal), modification of the usual medication will often suffice (Tables 2 and 3 ). Missing more than one perioperative meal is considered a prolonged starvation period. If the CBG is >12 mmol/L, it will necessitate either basal SC insulin or an intravenous insulin infusion.
Intraoperative
The intraoperative phase starts at the time of arrival in theatre and continues until transfer to the postoperative ward. The patient with DM must have a documented CBG prior to commencement of anaesthesia. While under anaesthesia, the CBG should be monitored at least 2-hourly, more frequently if abnormal and in patients receiving insulin. [18] If the intraoperative CBG levels were abnormal, the CBG measurement should be repeated in the post-anaesthetic recovery area.
When possible, administer SC short-or rapid-acting insulin to avoid unnecessary intravenous insulin for short surgical procedures. Limit SC short-or rapid-acting insulin to two intraoperative doses. In type 2 DM, a first dose of 0.1 U/kg (up to a maximum of 6 U) is appropriate; alternatively, use the correction dosing scale in Fig. 1 as a starting point. To prevent insulin stacking intraoperatively, do not administer a top-up dose of SC insulin within 2 hours of the first dose. Intravenous insulin is preferred when SC insulin does not control hyperglycaemia. This is common in surgery of longer duration, prolonged starvation and emergency cases. [11] 
Postoperative
After surgery, intravenous insulin therapy must not be discontinued without overlapping and restarting the patient's basal SC insulin. Check the CBG before discharge from the post-anaesthetic recovery area. Ensure that the patient is sent to the appropriate level of care for continuation of their glycaemic control strategy. Early reinstatement of normal enteral feeding and usual antidiabetic medication is the goal. The agents and regimen used for glycaemic control will largely depend on the feeding status of the patient (Table 4) .
Safe insulin therapy
Insulin is an extremely potent agent. Drug errors can cause significant harm to the patient. Staff education and involvement of the local pharmacy are needed to ensure constant safe prescribing, dispensing and dosing practices. [19] There is a real risk of diabetic ketoacidosis (DKA) with transition to and from intravenous insulin therapy. Delays in commencing the intravenous insulin infusion, and discontinuation of the infusion prior to administration of basal insulin, cause acute insulin deficiency in insulin-dependent patients. [20] This risk can be mitigated by continuation of basal SC insulin while using intravenous insulin, or by administration of intermediate-or long-acting insulin 30 minutes before discontinuing the intravenous insulin (GIK or VRIII). [12] 
Non-insulin antidiabetic agents
Non-insulin antidiabetic agents should not be started in the immediate perioperative period. These medications have multiple contraindications and are not rapidly titratable. However, diabetic patients who are well controlled could be considered for continuation of their non-insulin agents during the perioperative period. Guidance Appropriate where no more than one meal missed in the perioperative period. ‡ Check capillary blood glucose regularly while fasting. The majority of international guidelines advise 1-or 2-hourly measurements. Protocols with a 4-hourly measurement interval carry a 10% hypoglycaemia risk. [18] on the management of these agents during the perioperative period is given in Table 2 . Modification of oral therapy as the primary perioperative glycaemic control strategy is only appropriate in uncomplicated surgical patients who miss one meal during the perioperative period. Critically ill patients, those with poor glycaemic control and those who miss multiple meals, should be managed with an appropriate insulin regimen. [21, 22] 
Hypoglycaemia
The perioperative period represents an increased risk for undiagnosed hypoglycaemia while patients are fasting and under the influence of sedative agents. Whenever insulin is prescribed in hospital, hypoglycaemia treatment must be prescribed on the same chart. Perioperatively, a CBG <6.0 mmol/L should be interpreted as imminent hypoglycaemia. A CBG <4.0 mmol/L is associated with harm and must be treated. Interruption of insulin therapy is discouraged, but dose reduction may be necessary. Assess the patient with a low CBG for signs and symptoms of hypoglycaemia. Consider their feeding status (eating or fasting) and their risk of hypoglycaemia unawareness. Fig. 3 provides a suggested hypoglycaemia management algorithm. While under the influence of anaesthesia, treat all patients with a low CBG with intravenous dextrose. If the CBG is ˂6.0 mmol/L, administer 10 g intravenous dextrose; if the CBG is ˂4.0 mmol/L, give 20 g intravenous dextrose. Thereafter, the CBG should be measured every 15 minutes and treatment repeated until the blood glucose is corrected. [11] Special circumstances SC [23, 24] For patients with DM, day-case surgery must be considered. [14] It reduces the risk of iatrogenic complications and empowers the patient to manage their own perioperative glycaemic control. When assessing diabetic patients for day-case surgery, three aspects must be considered:
• Is the patient physically, mentally and socioeconomically capable to self-manage their DM and do they have easy access to emergency healthcare should they need it? • Is their DM adequately controlled, with a recent HbA1c <8.5%? • Is the nature of the surgery suitable for a day case?
A multidisciplinary contextsensitive approach
No single scenario describes every patient with DM who has to undergo surgery. At each facility (or group of facilities) a representative multidisciplinary team must evaluate the unique patient-resource environment and develop an evidence-based clinical practice guideline that fits their context. Smaller facilities should obtain input from their regional specialist centre. It is essential to empower patients to selfmanage their diabetes, especially in a setting where access to resources or healthcare personnel is limited. When appropriate, patients should be given guidance to manage their own insulin and non-insulin antidiabetic therapy in the ward. [21] The dietician, or equivalent team member, must engage the kitchen service to ensure To prevent insulin stacking, allow at least 4 hours between SC doses of insulin Two-hourly dosing is acceptable intraoperatively Reduce the basal doses to 80% of the usual dose on the night before and the morning of surgery Omit prandial dosing while fasting Provide hypoglycaemia management instructions wherever insulin is prescribed Fig. 1 . Basal-bolus insulin regimen. [16, 25, 26] (TDD = total daily dose; CBG = capillary blood glucose; SC = subcutaneous.) CME Box 1. Alberti glucose-insulin-potassium infusion [ 
21,27]
The GIK infusion is an alternative IV insulin regimen when a VRIII is not feasible. It provides substrate, IV insulin and electrolytes via a single infusion. The original GIK regimen was published by Alberti and Thomas in 1979. It provides a safe and effective method of giving substrate, IV insulin in the same infusion. Alterations of the original regimen remain in use today. [28, 29, 30] The original GIK regimen uses a bag containing 500 mL 10% dextrose and adds:
• 10 U short-acting insulin • 10 mL 10% KCl.
The infusion runs at a fixed rate of 100 mL/h, providing 2 U insulin per hour. CBG is measured 1 -2-hourly. To increase or decrease the insulin infusion rate by 1 U/h the insulin content of the bag is changed up or down by 5 U. A new bag must be mixed each time it is decided to adjust the insulin infusion rate. Problems with the GIK infusion are:
• labour intensive and wasteful when multiple bag changes are needed • maintenance at 100 mL/h exceeds current standards for care of surgical patients • 500 mL 10% dextrose bags are not available at all locations • 10% dextrose water is not an acceptable maintenance fluid • risk of DKA in type 1 DM if GIK infusion is stopped.
If deemed appropriate for the location, the local multidisciplinary team must adapt the GIK regimen to suite their context and address the concerns mentioned. Involve specialist input. GIK = glucose-insulin-potassium; IV = intravenous; VRIII = variable rate intravenous insulin infusion; CBG = capillary blood glucose; DKA = diabetic ketoacidosis; DM = diabetes mellitus.
Use a dedicated IV access site and infusion set with an antireflux valve for glucose management Add 50 U of regular short-acting insulin to 50 mL 0.9% NaCl (1 mL = 1 U) Administer with a syringe driver connected to a port close to the dedicated IV cannula Run dextrose-containing maintenance solution at 25 mL/kg/day (20 -30 mL/kg/h range) Monitor serum Na + and K + daily Measure CBG hourly while the patient is under the influence of anaesthesia; 2-hourly if normoglycaemic, awake, attended, and not confused There is a risk of DKA when discontinuing a VRIII, as it creates a state of acute insulin withdrawal Continue SC basal insulin while using a VRIII or administer SC basal insulin 30 min before discontinuing a VRIII Fig. 2 . Variable rate intravenous insulin infusion regimen. [21, 22] (CBG = capillary blood glucose; IV = intravenous; TDD = total daily dose; VRIII = variable rate intravenous insulin infusion; SC = subcutaneous; DKA = diabetic ketoacidosis.) that the diabetic diet provides a constant caloric intake from meal to meal and day to day. This will reduce prandial fluctuations in blood glucose and reduce the need for correction doses of insulin. The surgical team should understand the meal plan to ensure that minimal time elapses from the start of preoperative fasting until the first postoperative meal.
The local protocol should consider how care will be escalated for selected patients. Every DM patient cannot be referred to a diabeto logist. Also define how feedback on perioperative DM management will be used to bring the patient back into the primary healthcare system after the perioperative period.
Conclusion
DM is an ever-growing public health problem affecting patient outcomes after surgery. This article addresses the SA scope of the problem and provides a structure for managing the patient with DM presenting for surgery. A local multidisciplinary team should guide practice at each facility. The recommended reading section provides essential information for individual perioperative providers and teams caring for surgical patients with DM. Where a patient scenario falls outside the scope of this discussion, the provider must consult the local multidisciplinary team or referral specialist centre for guidance.
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